Takeda Pharmaceuticals (TAK) remains a hold, with shares near 52-week highs and uncertainty about a

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Takeda Pharmaceutical Co. Ltd.‘s

Takeda secured FDA approval for ORZEYFUL, a first-in-class oral orexin treatment for adults with nar

Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced that the U.S.

The FDA has approved Takeda Pharmaceuticals' oral drug for narcolepsy, the U.S. ​health regulator sa

ELRiSE MDS is a Phase 3, multicenter, open-label, randomized trial to compare the efficacy and safet

Takeda Pharmaceutical Company Limited (TAK) Q1 2027 Earnings Call Transcript

Takeda Pharmaceutical Co (NYSE:TAK) affirms FY2026 Adj EPS guidance from $3.01 to $3.01 vs $1.57 ana

Takeda Pharmaceutical NYSE: TAK said its first-quarter fiscal 2026 results were in line with its ful

Takeda Pharmaceutical Co (NYSE:TAK) affirms FY2026 GAAP EPS guidance from $0.66 to $0.66. Affirms FY

Takeda Pharmaceutical (NYSE:TAK) reported quarterly earnings of $0.48 per share which beat the analy

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced financial results for the firs

Arrowstreet Capital Limited Partnership trimmed its position in shares of Takeda Pharmaceutical Co.

Takeda Pharmaceutical (NYSE: TAK - Get Free Report) and Medicure (OTCMKTS:MCUJF - Get Free Report) a

Takeda Pharmaceutical (NYSE: TAK - Get Free Report) is anticipated to post its Q1 2027 results befor

Japanese drugmaker ​Takeda Pharmaceutical's ‌dengue vaccine ​QDENGA ​has been approved ⁠by ​India's

Takeda Pharmaceutical Co. Ltd. (NYSE:TAK) on Friday revealed encouraging secondary data from two piv

Takeda shares positive Phase 3 data for its oral psoriasis drug zasocitinib, showing high skin clear

New data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly se

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced new data from

The developer of the world’s first end-to-end AI drug has projected a big leap in half-year earnings

Ministry of Health of the Republic of Indonesia Grants Plasma Fractionation License, Enabling Takeda

OSAKA, Japan & CAMBRIDGE, Mass. & JAKARTA, Indonesia--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) an

Takeda and Insilico Medicine launch a strategic AI drug discovery collaboration to identify next-gen

Partnership to leverage Pharma.AI platform for novel drug candidates across Takeda's therapeutic are

Takeda is set to pay InSilico to use its proprietary Pharma. AI platform to advance drug candidates

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology c

Silence Therapeutics ($SLN) stock surges as Cantor predicts key August Phase 2 data will be a major

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--In the final step of its 18-month CEO transition,

Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primar

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today presented additio

Silence Therapeutics says SANRECO data show sustained polycythemia vera benefits as analysts weigh d

Takeda's psoriasis drug zasocitinib outperformed Bristol Myers Squibb's Sotyktu in a Phase 3

Takeda ((TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-bl

Japan's Takeda Pharmaceutical said on Thursday its experimental once-daily psoriasis pill, developed

If approved, ENTYVIO would be the only gut-focused treatment for patients two years and older with m

Takeda faces nearly $885 million jury verdict in AMITIZA antitrust case and plans post-trial motions

Takeda eyes growth with FDA Priority Reviews for narcolepsy and PV drugs. Get the latest on TAK'

Takeda Pharmaceutical (NYSE:TAK) reported quarterly earnings of $0.28 per share which beat the analy

TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (

FDA clears Axsome's Auvelity for Alzheimer's agitation, backed by Phase 3 data, expanding it

Denali shares fall after Takeda exits DNL593 deal; company regains full rights and targets Phase 1/2

Denali plans to continue clinical development of DNL593, which is designed to deliver progranulin to

Axsome gains after securing global rights to balipodect from Takeda, advancing schizophrenia pipelin

Under the terms of the agreement, Axsome obtained worldwide commercial, development, and manufacturi

Takeda Canada Inc. ("Takeda") is pleased to announce new data from the two pivotal Phase 3 s

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at wee

Global CEOs signal cautious China expansion as Eli Lilly ramps investment, while the Supreme Court r